FDA Seen Needing To Fix Post-Market Drug Safety

September 25, 2006 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WASHINGTON (Reuters) - The U.S. Food and Drug Administration needs more staff and funding to fix its monitoring of drug safety after medicines are on the market, the Institute of Medicine (IOM) said on Friday.>>> Discuss This Story

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Merck & Co. Food and Drug Administration (FDA)